Chikungunya: a risk for Mediterranean countries?

Acta Trop

Institut Pasteur, Génétique moléculaire des Bunyavirus, 25-28 rue du Dr Roux, F-75724 Paris cedex 15, France.

Published: February 2008

The Italian outbreak of the 2007 summer and the active spreading of the Asian tiger mosquito Aedes albopictus in southern Europe, raise the possibility of local transmission of chikungunya (CHIK) in Mediterranean countries. Established in at least 12 countries in southern Europe since the end of the 1970s and in southern France since 2004, Ae. albopictus, is invading the French Mediterranean coast from East to West. To determine the possibility of an outbreak of CHIK in southern France, we provide an assessment of vector competence towards CHIK virus of different mosquito species, including Ae. albopictus, collected in 2006 in Camargue and the "Côte d'Azur" (Alpes Maritimes). In the laboratory, Ae. albopictus showed a high susceptibility to CHIK infection (77.1%) comparable to that observed for specimens collected in March 2006 in La Reunion Island. Hence, Ae. albopictus from southern France has the potential to serve as a vector based on its susceptibility to CHIK infection. Its presence in a tourist area such as the "Côte d'Azur" should be considered as a potential threat for the introduction of CHIK virus as in Italy where the initial case was probably a traveller coming back from an endemic zone.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.actatropica.2007.09.009DOI Listing

Publication Analysis

Top Keywords

southern france
12
albopictus southern
8
southern europe
8
chik virus
8
"côte d'azur"
8
susceptibility chik
8
chik infection
8
chik
6
albopictus
5
southern
5

Similar Publications

Article Synopsis
  • Ataluren was developed to help produce functional proteins in patients with cystic fibrosis caused by nonsense mutations, and this study aimed to assess its effectiveness and safety in such patients.
  • The trial was a randomized, double-blind, placebo-controlled phase 3 study that enrolled 238 patients from 36 sites across North America and Europe, administering ataluren or placebo over 48 weeks.
  • Results showed no significant difference in lung function (FEV1) change or pulmonary exacerbations between ataluren and placebo groups, but a notable improvement was observed in a subgroup of patients not using a specific antibiotic (tobramycin).
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!